Please try another search
Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological medicines, transplanted organs, and the body’s own cells or tissues in Sweden. The company develops IDO 8 that is designed for patients with haemophilia, who have developed antibodies against critical treatment with coagulation factor VIII. It also develops IDO T, a cell therapy for patients who are receiving kidney transplants; and IDO AID for the treatment of autoimmune diseases. The company was incorporated in 2008 and is headquartered in Lund, Sweden.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review